- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04523545
Safety & Clinical Performance Study of Catheter Ablation With the Centauri System for Patients With Atrial Fibrillation (ECLIPSE AF)
Safety & Performance Study of the Centauri System for Patients With Atrial Fibrillation
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Vikramaditya Mediratta, MS
- Phone Number: 714-717-2376
- Email: vmediratta@galaxymedical.com
Study Contact Backup
- Name: James Stambaugh
- Phone Number: 408-718-6834
- Email: jstambaugh@galatherapeutics.com
Study Locations
-
-
-
Split, Croatia, 21000
- Recruiting
- University Hospital of Split
-
Contact:
- Ivan Sikiric, MD
- Phone Number: 38521556255
- Email: ivan.sikiric20@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Failure of at least one antiarrhythmic drug (AAD) (Class I - IV) for AF, as evidenced by recurrent symptomatic AF or intolerable side effects due to AAD
Diagnosis of recurrent symptomatic paroxysmal AF (PAF) or short duration (< 1 year) Persistent AF (PeAF) with the following documentation:
a. PAF i. Physician's note indicating symptoms consistent with recurrent symptomatic PAF AND ii. ≥ 2 episodes of PAF within 12 months prior to enrollment. At least one episode should be documented by ECG, transtelephonic monitor (TTM), Holter monitor, telemetry strip or similar, showing at least 30 seconds of AF b. PeAF i. Physician's note indicating symptoms consistent with continuous AF episode lasting longer than 7 days but less than 1 year AND ii. Any 24-hour continuous ECG recording documenting persistent AF within 6 months prior to enrollment OR iii. Two ECGs from any form of rhythm monitoring showing continuous AF taken at least 7 days apart within 12 months prior to enrollment OR iv. History of direct current cardioversion (DCCV) performed within 12 months prior to enrollment
- Patient is indicated for an ablation procedure according to society guidelines or investigational site practice
- Patient is willing and able to give informed consent.
- Patient is willing, able and committed to participate in baseline and follow-up evaluations for the duration of the study.
Exclusion Criteria:
- Long-standing persistent AF (continuous AF sustained > 1 year)
- AF secondary to electrolyte imbalance, thyroid disease, alcohol abuse, or other reversible/non-cardiac causes
- Left atrial anteroposterior diameter > 5.0 cm as documented by transthoracic echocardiography (TTE) or computed tomography (CT) within 6 months prior to enrollment
- Use of amiodarone within 6 weeks prior to enrollment
- Prior left atrial ablation or surgical procedure (including left atrial appendage (LAA) device or occlusion)
- Planned LAA closure procedure or implant of a permanent pacemaker, biventricular pacemaker, loop recorder/insertable cardiac monitor (ICM), or any type of implantable cardiac defibrillator (with or without biventricular pacing function) for any time during the follow-up period
- Presence of a permanent pacemaker, biventricular pacemaker, loop recorder/insertable cardiac monitor (ICM), or any type of implantable cardiac defibrillator (with or without biventricular pacing function)
- Presence of any pulmonary vein stents
- Presence of any pre-existing pulmonary vein stenosis
- Pre-existing hemidiaphragmatic paralysis
- Atrial or ventricular septal defect closure
- Atrial myxoma
- Presence of any prosthetic heart valve
- Hemodynamically significant valvular disease
- History of pericarditis
- History of Rheumatic heart disease
- History of thromboembolic event within 6 months of time of enrollment or evidence of intracardiac thrombus at time of procedure
Any of the following events within 3 months of enrollment
- Myocardial infarction (MI)
- Unstable angina
- Percutaneous coronary intervention
- Heart surgery including coronary artery bypass grafting
- Heart failure hospitalization
- Cerebral ischemic event (stroke or transient ischemic attack (TIA))
- Clinically significant bleeding
- Pericardial effusion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
|
cardiac ablation using pulsed electric field energy to cause pulmonary vein isolation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute Procedural Success
Time Frame: During treatment procedure
|
Proportion of patients with confirmed pulmonary vein isolation (PVI) during the index procedure
|
During treatment procedure
|
Rate of device and procedure related serious adverse events
Time Frame: 30 days
|
The rate of system-related and procedure-related serious adverse events (SAEs)
|
30 days
|
Chronic Feasibility: Proportion of patients with documented electrical isolation of the pulmonary veins
Time Frame: 90 days
|
Proportion of patients with documented electrical isolation of the pulmonary veins
|
90 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSP-00007
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
Abbott Medical DevicesRecruitingAtrial Fibrillation | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited States, Australia, Belgium, Germany, Spain, Netherlands, France, Austria, Canada, Czechia, Italy, United Kingdom
-
Beijing Anzhen HospitalJohnson & Johnson; Heart Health Research CenterNot yet recruitingParoxysmal Atrial Fibrillation | Persistent Atrial Fibrillation
Clinical Trials on cardiac ablation
-
Medtronic Cardiac Rhythm and Heart FailureCompleted
-
Abbott Medical DevicesTerminated
-
Abbott Medical DevicesCompletedHypertension | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationGermany
-
Vektor MedicalExperien GroupCompletedAtrial Fibrillation | Ventricular Fibrillation | Ventricular Tachycardia | Ventricular Arrythmia | Cardiac Arrhythmia | Premature Ventricular Complexes Multiple | Premature Atrial Complex | Atrioventricular Reentrant TachycardiaUnited States
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaUnknownAtrioventricular Node ArrhythmiaCanada
-
Assiut UniversityWithdrawn
-
Xijing HospitalRecruiting
-
EPD Solutions, A Philips CompanyRecruitingAtrial Fibrillation and FlutterUnited States
-
Stanford UniversityWithdrawnAtrial Fibrillation | Obstructive Sleep ApneaUnited States